CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
about
Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphomaSuppression, subversion and escape: the role of regulatory T cells in cancer progressionSézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surfaceEvolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma.IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.Denileukin diftitox as novel targeted therapy for lymphoid malignancies.CD30 expression and proliferative fraction in nontransformed mycosis fungoidesRecombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignanciesOptimizing denileukin diftitox (Ontak) therapy.Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in childrenT-regulatory cell modulation: the future of cancer immunotherapy?Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.New targets of therapy in T-cell lymphomas.CD30+ neoplasms of the skin.Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.Brentuximab vedotin in systemic T-cell lymphoma.T-regulatory cells: key players in tumor immune escape and angiogenesis.CD25+ folliculotropic Sézary syndrome with CD30+ large cell transformation.Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.Targeting regulatory T cells in tumors.Correlations between clinical and pathological features in 17 cases of mycosis fungoides before and after transformation.Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force StudExpression of immune molecules CD25 and CXCL13 correlated with clinical severity of myasthenia gravis.High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.Brentuximab vedotin: clinical updates and practical guidance.Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor.
P2860
Q24626963-5EF545AA-84B6-4C83-B3CD-CF04256FDB9BQ27026151-4B8E9A84-F326-41B8-AE54-DF0F63ABCC6FQ34754395-FD5C06A4-84E5-4452-9512-1B77FDE70E38Q35022833-9BDECB50-DB32-410B-B804-994B41B25554Q35858578-96034C89-0E89-4EB8-B592-E64045EF0186Q36384826-0D53A160-FF60-49C7-A9C0-EDE61044F0CBQ36471121-8F55350A-DC6F-4646-8A35-C20C46BC5AF8Q36534677-9145D884-0BA7-426A-ABA4-DB5ECF8D589FQ36946771-2B41FEF8-4A8B-4104-9981-682C1C07A7EBQ37070128-A07EE69D-82A0-4923-8FBB-918E3903CDB0Q37165245-E785699F-AD14-4B3D-9C48-AA97F9C4620FQ37236406-A3FD5056-A193-4C57-A91B-FAC8DB5EE720Q37407590-37689366-0B0B-45B6-8ACE-A3C97A242972Q37454346-DC2EC2E3-2B1F-4FD4-910E-14FA245D4CAFQ37698501-0B79C979-6F8A-4137-A75C-9157217D8DBCQ37701472-A9A2C1D8-D971-4072-8205-9C89F364035FQ37919372-CD85F32C-C5B9-4ADB-B2B6-3E4482974D25Q37944565-0C2F25C7-DD4D-4EDD-B9D1-13F98FEAC68FQ37994753-6A0F0CF7-5B6D-40B3-9CA7-9BDD2A290442Q38006901-A6F4583F-7FBD-4FC0-B835-4C5AFCF76143Q38063343-E81C7031-08F0-4557-A74D-106CE9A562A3Q38565385-1E03690B-56C4-4A84-9CC0-540B1228C0F4Q38703565-A50536EA-B854-4A06-942A-507602B49604Q40765544-03B64EF8-9BA3-4355-BACA-297A2C09DD5DQ41086530-9C624B59-2656-4600-8C16-78AB3CC03AE0Q45344123-4DCEBFE4-E4BD-4230-93BB-2F4315168A22Q47856794-B0A7DD98-BF29-4D73-89BC-D98C03C65C93Q49282959-78A08B69-D2C5-441B-BF21-0100A914EC03Q50630512-849A1FCF-3308-4D7D-8F5D-8A86FA108CC2Q53090167-7093C468-25BC-4522-A9EE-EFABF8EA18FF
P2860
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
CD25 expression is correlated ...... in cutaneous T-cell lymphoma.
@en
CD25 expression is correlated ...... in cutaneous T-cell lymphoma.
@nl
type
label
CD25 expression is correlated ...... in cutaneous T-cell lymphoma.
@en
CD25 expression is correlated ...... in cutaneous T-cell lymphoma.
@nl
prefLabel
CD25 expression is correlated ...... in cutaneous T-cell lymphoma.
@en
CD25 expression is correlated ...... in cutaneous T-cell lymphoma.
@nl
P2093
P356
P1476
CD25 expression is correlated ...... in cutaneous T-cell lymphoma.
@en
P2093
Alvaro J Alencar
Daniel M Jones
Kelly L Herne
Madeleine Duvic
Narin Apisarnthanarax
Rakhshandra Talpur
P2888
P304
P356
10.1038/SJ.JID.5700122
P407
P577
2006-03-01T00:00:00Z